Saturday 17 October 2026
Export JNJ’s income statement to Excel — free account
Johnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.
255.55
2.27
+0.90%
Follow JNJ
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
18.73 | 28.26 | 29.43 | 30.68 |
P/S ratio |
5.29 | 6.11 | 6.24 | 6.42 | |
P/FCF ratio |
24.40 | 32.26 | 26.91 | 28.05 | |
P/Operating CF |
68.16 | 234.20 | 70.96 | 73.97 | |
P/B ratio |
6.11 | 7.25 | 7.20 | 7.50 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.49 | 6.27 | 6.41 | 6.58 | |
EV/EBITDA |
12.29 | 17.43 | 18.01 | 18.75 | |
EV/Operating CF |
21.10 | 26.42 | 22.75 | 23.69 | |
EV/FCF |
25.35 | 33.10 | 27.64 | 28.78 | |
Quick Ratio |
0.69 | 0.69 | 0.73 | — | |
Current Ratio |
1.03 | 1.03 | 1.09 | — | |
Net Debt/EBITDA |
2.60 | 1.82 | 1.80 | — | |
Debt/Assets |
19.80% | 18.68% | 18.57% | — | |
Debt/Equity |
0.48 | 0.46 | 0.44 | — | |
Asset Turnover |
0.50 | 0.49 | 0.50 | 0.00 | |
Operating CF/Net income |
1.43 | 0.48 | 1.56 | 0.00 | |
Capex/Depreciation |
(0.76) | (0.51) | (0.64) | — | |
Interest Coverage |
25.31 | 23.86 | 25.79 | — | |
Research and Development Expense of Revenue |
17.31% | 14.66% | 14.43% | 18.32% | |
Selling, General and Administrative Expense of Revenue |
27.49% | 25.08% | 25.41% | 24.75% | |
Intangible Assets out of Total Assets |
0.50 | 0.49 | 0.48 | — | |
Share Based Compensation of Revenue |
1.26% | 1.25% | 1.81% | 0.00% | |
Graham Net Nets |
(0.12) | (0.10) | (0.09) | (0.09) | |
Graham Number |
91.77 | 80.99 | 82.79 | — | |
Earnings Yield |
5.34% | 3.54% | 3.40% | 3.26% | |
Free Cash Flow Yield |
4.10% | 3.10% | 3.72% | 3.57% | |
Revenue per Share |
10.20 | 9.99 | 10.51 | 0.00 | |
Operating CF per Share |
3.04 | 1.04 | 3.58 | — | |
Capex per Share |
(0.63) | (0.42) | (0.52) | — | |
Free Cash Flow per Share |
2.40 | 0.62 | 3.06 | — | |
Cash per Share |
8.35 | 9.15 | 8.62 | — | |
Shareholders Equity per Share |
33.87 | 33.71 | 35.30 | — | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | |
Book value per Share |
33.87 | 33.71 | 35.30 | — | |
Free Cash Flow |
5,784.00 | 1,494.00 | 7,358.00 | — | |
Working Capital |
1,498.00 | 1,457.00 | 4,879.00 | — | |
Capital Expenditures |
(1,525.00) | (1,020.00) | (1,258.00) | — | |
Net Current Asset Value |
(62,042.00) | (60,535.00) | (56,316.00) | — | |
EV/EBIT |
14.95 | 22.44 | 23.16 | 34.13 | |
Capex to Sales |
0.06 | 0.04 | 0.05 | 0.00 | |
Price to Operating Income |
15.29 | 23.61 | 24.27 | 35.93 | |
| Other line items | |||||
Average Receivables |
16,010.00 | 16,870.50 | 18,446.00 | — | |
Average Payables |
11,151.00 | 10,002.50 | 9,343.50 | — | |
Average Inventory |
13,317.50 | 13,621.00 | 14,278.00 | — | |
Average Assets |
189,657.00 | 197,282.50 | 197,225.00 | — | |
Average Common Equity |
76,517.00 | 79,647.50 | 81,722.00 | — |
Columns are period end dates · fundamentals updated 14 Oct 2026